Posted On: 03/13/2014 7:47:09 AM
Post# of 80
Latest Dynavax Technologies Corp (DVAX) Headlines
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.
Scandal-Ridden SAC Capital Buys Broadcom, Dynavax, and Boston Scientific
Selena Maranjian, The Motley Fool - Motley Fool - Fri Mar 07, 4:44PM CST
The latest 13F season has arrived, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling....
Will Dynavax (DVAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:19AM CST
Will Dynavax (DVAX) Continue to Surge Higher?
Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.
Dynavax to receive USD5.4m milestone payment from AstraZeneca under the Phase 1 clinical study of AZD1419
M2 - Tue Mar 04, 7:06AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) revealed on Monday the receipt of a USD5.4m milestone payment from its biopharmaceutical business collaborator, AstraZeneca.
Dynavax to Receive $5.4 Million Milestone
Marketwire - Mon Mar 03, 3:00PM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced a $5.4 million milestone payment from its collaborator, AstraZeneca. The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, following completion of the ongoing Phase 1 clinical study of AZD1419 for the treatment of asthma.
Dynavax to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Fri Feb 28, 3:00PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
SINA Q4 Makes More Money
SinoCast - Tue Feb 25, 4:21AM CST
SINA Corporation (Nasdaq: SINA) revealed net operating revenue of USD 197 million in fourth quarter ended December 31, 2013, rising 42% from a year earlier. Net profit reached USD 44.5 million, in contrast to USD 2.4 million a year earlier, representing USD 0.59 per share after being diluted, in contrast to USD 0.03 a year ago.
We Need a Modern Plan to Enrich Soil [column]
by Alex O. Awiti - All Africa Global Media - Tue Feb 25, 4:20AM CST
Over 95 percent of smallholder farms in Kenya show severe depletion of essential soil nutrients - nitrogen, phosphorous and potassium. Moreover, Kenya's agricultural soils have dangerously low soil organic matter and exhibit worrying trends of acidification. This is according to a report by the National Accelerated Agricultural Input Access Programme (NAAIAP) released February 18, 2014.
Dynavax Withdraws MAA on Heplisav - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:20PM CST
Dynavax recently announced it has withdrawn its MAA for Heplisav.
3 Biotech Stocks with Great Upside: Inovio Pharmaceuticals, Dynavax, and Ariad
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
In a previous article, I discussed three fallen biotech stocks that were unlikely to bounce back anytime soon. In this article, I'll focus on three biotech stocks that could rally higher in 2014 -- Inovio Pharmaceuticals , ...
Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV(TM)
Marketwire - Tue Feb 18, 8:03AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has withdrawn the European Marketing Authorization Application (MAA) for HEPLISAV, its investigational hepatitis B vaccine. The Day 180 List of Outstanding Issues provided by the European Medicines Agency (EMA) indicated that the current HEPLISAV safety database is considered to be too small to rule out a risk of less common serious adverse events. Dynavax has chosen to withdraw the application because the required timeframe for response under the MAA procedure is not long enough to permit the collection of the necessary clinical data. Dynavax expects to begin shortly an additional HEPLISAV clinical trial, HBV-23, that is intended to provide a safety database sufficient to support licensure.
Frost & Sullivan: Multichannel and Technology-Enabled Solutions Drive Growth in the North American Contact Center Outsourcing Market
PR Newswire - Wed Feb 12, 6:52AM CST
Rapid change characterizes today's customer contact landscape. Consider that an increasingly influential Generation Y has high purchasing power and continues to experiment with new technologies. Indeed, impactful consumer trends, combined with the proliferation and expansion of automated and non-voice channels, is driving momentum in the realm of technology-based customer service specifically. As a result, while the explosive growth of social media has helped create a cacophony of consumer voices, enterprises are looking to outsourced service providers more than ever for guidance on social media strategies, technologies, and tactics. In essence, in 2014, contact centers are viewed as a central place from which a company's "brand advocates" can improve the Customer Experience while negotiating social customer behavior via channels such as blogs, customer forums, YouTube, Facebook, Twitter and Google.
See What These $17 Billion Outperformers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon Feb 10, 4:35PM CST
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at Westfield Capital Management, an investment advisor serving...
End of Chinese New Year and Public Offerings Spur Penny-Stock Volume: DryShips Inc. (NASDAQ: DRYS), FuelCell Energy Inc. (NASDAQ: FCEL), Dynavax Technologies Corp. (NASDAQ: DVAX)
ACCESSWIRE - Mon Feb 10, 10:05AM CST
The Ying and Yang of economic news fueled the volume of the most active penny stocks at the close of the market Feb 7, 2014.
Hot Stock: Dynavax Technologies, Shares Drop 6.5% (DVAX)
Comtex SmarTrend(R) - Mon Jan 27, 10:12AM CST
Dynavax Technologies (NASDAQVAX) is one of today's worst performing low-priced stocks, down 6.5% to $1.74 on 1.1x average daily volume. Dynavax Technologies has traded 5.4 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-6.5% to the Dow's 0.1%) and underperformed the S&P 500 (-6.5% to the S&P's -0.3%) during today's trading.
Chinese Manufacturing Slowdown Could Nix DryShips Recovery: DryShips Inc. (NASDAQ: DRYS), Dynavax Technologies Corp. (NASDAQ: DVAX), FuelCell Energy Inc. (NASDAQ: FCEL)
ACCESSWIRE - Mon Jan 27, 7:07AM CST
DryShips Inc. (NASDAQ: DRYS) stock volume soared at the close of the market Jan. 24 with 26,149,820 shares changing hands, making it one of the most actively traded penny stocks for the day. But it's unclear if DryShips' high share volume is being driven by this potentially positive news or the negative news that Chinese manufacturing is sputtering to a slowdown. According to the New York Times, the flash Markit/HSBC Purchasing Managers' Index fell to 49.6 in January from December's final reading of 50.5. Economists contend when this index drops below 50 it signals the beginning of an economic contraction. This concern comes only a few weeks after the Athens, Greece diversified marine transportation company said that it would continue its previously-announced program to issue $200 million in common stock in an at-the-market offering with Evercore Group LLC as its sales agent. In need of a recovery DryShip's recent offering is expected to provide the estimated $150 million the company needs to operate through 2014. This influx of needed capital helps to erase the negative news of Dec. 5, when the company suspended its equity offering with share price of about $3.60. But, any shipping company's recovery depends a lot on prevailing economic conditions.
Most Active Stocks Range from Online Game Maker to Biopharmaceuticals: Zynga Inc. (NASDAQ:ZNGA), Dynavax Technologies Corp. (NASDAQ: DVAX), Cell Therapeutics Inc. (NASDAQ:CTIC)
ACCESSWIRE - Mon Jan 20, 6:22AM CST
San Francisco-based online game maker Zynga Inc. (NASDAQ:ZNGA) is one of the most active stocks with 80,439,048 shares changing hands on Jan. 16, 2014.
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...
Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.
Scandal-Ridden SAC Capital Buys Broadcom, Dynavax, and Boston Scientific
Selena Maranjian, The Motley Fool - Motley Fool - Fri Mar 07, 4:44PM CST
The latest 13F season has arrived, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling....
Will Dynavax (DVAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:19AM CST
Will Dynavax (DVAX) Continue to Surge Higher?
Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.
Dynavax to receive USD5.4m milestone payment from AstraZeneca under the Phase 1 clinical study of AZD1419
M2 - Tue Mar 04, 7:06AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) revealed on Monday the receipt of a USD5.4m milestone payment from its biopharmaceutical business collaborator, AstraZeneca. Dynavax to Receive $5.4 Million Milestone
Marketwire - Mon Mar 03, 3:00PM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced a $5.4 million milestone payment from its collaborator, AstraZeneca. The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, following completion of the ongoing Phase 1 clinical study of AZD1419 for the treatment of asthma.
Dynavax to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Fri Feb 28, 3:00PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
SINA Q4 Makes More Money
SinoCast - Tue Feb 25, 4:21AM CST
SINA Corporation (Nasdaq: SINA) revealed net operating revenue of USD 197 million in fourth quarter ended December 31, 2013, rising 42% from a year earlier. Net profit reached USD 44.5 million, in contrast to USD 2.4 million a year earlier, representing USD 0.59 per share after being diluted, in contrast to USD 0.03 a year ago.
We Need a Modern Plan to Enrich Soil [column]
by Alex O. Awiti - All Africa Global Media - Tue Feb 25, 4:20AM CST
Over 95 percent of smallholder farms in Kenya show severe depletion of essential soil nutrients - nitrogen, phosphorous and potassium. Moreover, Kenya's agricultural soils have dangerously low soil organic matter and exhibit worrying trends of acidification. This is according to a report by the National Accelerated Agricultural Input Access Programme (NAAIAP) released February 18, 2014.
Dynavax Withdraws MAA on Heplisav - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:20PM CST
Dynavax recently announced it has withdrawn its MAA for Heplisav.
3 Biotech Stocks with Great Upside: Inovio Pharmaceuticals, Dynavax, and Ariad
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
In a previous article, I discussed three fallen biotech stocks that were unlikely to bounce back anytime soon. In this article, I'll focus on three biotech stocks that could rally higher in 2014 -- Inovio Pharmaceuticals , ...
Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV(TM)
Marketwire - Tue Feb 18, 8:03AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has withdrawn the European Marketing Authorization Application (MAA) for HEPLISAV, its investigational hepatitis B vaccine. The Day 180 List of Outstanding Issues provided by the European Medicines Agency (EMA) indicated that the current HEPLISAV safety database is considered to be too small to rule out a risk of less common serious adverse events. Dynavax has chosen to withdraw the application because the required timeframe for response under the MAA procedure is not long enough to permit the collection of the necessary clinical data. Dynavax expects to begin shortly an additional HEPLISAV clinical trial, HBV-23, that is intended to provide a safety database sufficient to support licensure.
Frost & Sullivan: Multichannel and Technology-Enabled Solutions Drive Growth in the North American Contact Center Outsourcing Market
PR Newswire - Wed Feb 12, 6:52AM CST
Rapid change characterizes today's customer contact landscape. Consider that an increasingly influential Generation Y has high purchasing power and continues to experiment with new technologies. Indeed, impactful consumer trends, combined with the proliferation and expansion of automated and non-voice channels, is driving momentum in the realm of technology-based customer service specifically. As a result, while the explosive growth of social media has helped create a cacophony of consumer voices, enterprises are looking to outsourced service providers more than ever for guidance on social media strategies, technologies, and tactics. In essence, in 2014, contact centers are viewed as a central place from which a company's "brand advocates" can improve the Customer Experience while negotiating social customer behavior via channels such as blogs, customer forums, YouTube, Facebook, Twitter and Google.
See What These $17 Billion Outperformers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon Feb 10, 4:35PM CST
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at Westfield Capital Management, an investment advisor serving...
End of Chinese New Year and Public Offerings Spur Penny-Stock Volume: DryShips Inc. (NASDAQ: DRYS), FuelCell Energy Inc. (NASDAQ: FCEL), Dynavax Technologies Corp. (NASDAQ: DVAX)
ACCESSWIRE - Mon Feb 10, 10:05AM CST
The Ying and Yang of economic news fueled the volume of the most active penny stocks at the close of the market Feb 7, 2014.
Hot Stock: Dynavax Technologies, Shares Drop 6.5% (DVAX)
Comtex SmarTrend(R) - Mon Jan 27, 10:12AM CST
Dynavax Technologies (NASDAQ
VAX) is one of today's worst performing low-priced stocks, down 6.5% to $1.74 on 1.1x average daily volume. Dynavax Technologies has traded 5.4 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-6.5% to the Dow's 0.1%) and underperformed the S&P 500 (-6.5% to the S&P's -0.3%) during today's trading. Chinese Manufacturing Slowdown Could Nix DryShips Recovery: DryShips Inc. (NASDAQ: DRYS), Dynavax Technologies Corp. (NASDAQ: DVAX), FuelCell Energy Inc. (NASDAQ: FCEL)
ACCESSWIRE - Mon Jan 27, 7:07AM CST
DryShips Inc. (NASDAQ: DRYS) stock volume soared at the close of the market Jan. 24 with 26,149,820 shares changing hands, making it one of the most actively traded penny stocks for the day. But it's unclear if DryShips' high share volume is being driven by this potentially positive news or the negative news that Chinese manufacturing is sputtering to a slowdown. According to the New York Times, the flash Markit/HSBC Purchasing Managers' Index fell to 49.6 in January from December's final reading of 50.5. Economists contend when this index drops below 50 it signals the beginning of an economic contraction. This concern comes only a few weeks after the Athens, Greece diversified marine transportation company said that it would continue its previously-announced program to issue $200 million in common stock in an at-the-market offering with Evercore Group LLC as its sales agent. In need of a recovery DryShip's recent offering is expected to provide the estimated $150 million the company needs to operate through 2014. This influx of needed capital helps to erase the negative news of Dec. 5, when the company suspended its equity offering with share price of about $3.60. But, any shipping company's recovery depends a lot on prevailing economic conditions.
Most Active Stocks Range from Online Game Maker to Biopharmaceuticals: Zynga Inc. (NASDAQ:ZNGA), Dynavax Technologies Corp. (NASDAQ: DVAX), Cell Therapeutics Inc. (NASDAQ:CTIC)
ACCESSWIRE - Mon Jan 20, 6:22AM CST
San Francisco-based online game maker Zynga Inc. (NASDAQ:ZNGA) is one of the most active stocks with 80,439,048 shares changing hands on Jan. 16, 2014.
(0)
(0)Scroll down for more posts ▼
